Stock Taper
SCREENER COMPARE ANY 2 STOCKS
DNTH
DIANTHUS THERAPEUTICS, INC.
NASDAQ
$105.84
▼ DOWN 5.11% (-5.70)

KEY STATISTICS

Market Cap$5.92 B
52w High$117.88
52w Low$23.39
Dividend Yield—
Frequency—
P/E-25.50
Volume376.18K
Shares Out.55.93M

COMPANY

LEADERSHIP

Marino Garcia
CHIEF EXECUTIVE
Marino Garcia

COMPENSATION 2026

Salary$630,000
Stock Awards$0
Incentive Plan Pay$519,750
All Other Comp.$14,000
Total$10,614,702

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 21, 2018
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
92

PRICE TARGET

Target High$158.00
Target Low$98.00
Target Median$122.00
Target Consensus$124.18

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$400.83K
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2023-09-12Reverse1:16

PRICE

$105.84 ▼ DOWN 5.11% (−$5.70)
OVERLAYS
$106$108$110$1129:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM105.84

About Dianthus Therapeutics, Inc.

https://dianthustx.com ↗

Dianthus Therapeutics, Inc., a New York-based clinical-stage biotech founded in 2015, develops novel monoclonal antibodies like DNTH103 for severe autoimmune and inflammatory diseases, currently in Phase 1 trials.

INDUSTRY

Biotechnology

A PRODUCT DIANTHUS THERAPEUTICS, INC. IS KNOWN FOR

Claseprubart (DNTH103)
Claseprubart (DNTH103)

Claseprubart, Dianthus Therapeutics' lead long-acting monoclonal antibody, selectively inhibits C1s to treat autoimmune diseases like gMG, MMN, and CIDP, and is in mid-to-late-stage trials as a self-administered subcutaneous injection.

COMPETITORS

COMPETITOR
ARGX COMPARE
CYTK COMPARE
KRYS COMPARE
PRAX COMPARE
SNY COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License$396K $1.45M ▲$463K ▼$761K ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
142
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.01% · 3.1M
XBI
1.30% · 1.4M
IWM
0.17% · 1.2M
SCHA
0.09% · 190.1K
TCAF
0.20% · 149.9K
DFAS
0.05% · 71.2K
SBIO
2.96% · 67.3K
FYC
0.44% · 57.4K
LABU
0.88% · 50.4K
XRS2.F
0.17% · 43.2K
USVM
0.24% · 38.0K
LFSC
2.70% · 32.3K
FESM
0.05% · 29.5K
RSSL
0.17% · 22.6K
PRFZ
0.06% · 15.1K
BBSC
0.16% · 10.9K
GSSC
0.10% · 9.6K
BBC
0.81% · 3.8K
RTWO.L
0.12% · 2.5K
URTY
0.06% · 1.9K
BKSE
0.20% · 1.7K
RFLR
0.14% · 1.3K
TILT
0.00% · 810
PWS
0.27% · 603
USFMDN.MX
0.01% · 186
RESM
0.16% · 90

INSTITUTIONAL OWNERSHIP

SHARES OWNED
71.87%
HOLDERS
326
TOP 12 OF 326 · RANKED BY POSITION SIZE
Fmr LLC
8.2M sh · $799.33M
Blackrock, Inc.
4.1M sh · $401.99M
T. Rowe Price Investment Management, Inc.
3.9M sh · $379.05M
Fairmount Funds Management LLC
3.3M sh · $130.14M
Wellington Management Group Llp
3.2M sh · $314.85M
Avidity Partners Management LP
3.2M sh · $126.08M
Ra Capital Management, L.P.
2.9M sh · $112.81M
Price T Rowe Associates Inc /Md/
2.5M sh · $245.16M
Octagon Capital Advisors LP
2.4M sh · $99.59M
State Street Corp
2.4M sh · $229.8M
Vanguard Group Inc
2.0M sh · $84.42M
Point72 Asset Management, L.P.
2.0M sh · $80.35M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
Read Simon
Sale · 2.8K shares
2026-08-19
★
DIRECTOR
Read Simon
Purchase · 2.8K shares
2026-08-19
★
OFFICER: SVP, GENERAL COUNSEL AND SEC.
Veness Adam M
Sale · 15.0K shares
2026-08-13
★
OFFICER: SVP, GENERAL COUNSEL AND SEC.
Veness Adam M
Purchase · 15.0K shares
2026-08-13

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OUTPERFORM 4
STRONG BUY 1
11 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Truist Securities BUY Wedbush OUTPERFORM Evercore ISI Group OUTPERFORM Baird OUTPERFORM Clear Street BUY Raymond James STRONG BUY Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
ELVN$57.86COMPARE
ATAI$7.29COMPARE
NKTR$72.52COMPARE
TSHA$5.77COMPARE
ANAB$56.28COMPARE
IMTX$9.45COMPARE
SANA$3.93COMPARE
BBOT$8.74COMPARE